The Utilisation Rate of Clozapine for Treatment Resistant Schizophrenia Within Trustwide Adult Inpatient Services Over One Year

Aims The audit was undertaken to explore if inpatients with treatment resistant schizophrenia (TRS), or whose condition has not adequately responded two antipsychotics of an optimal duration and dose, were offered clozapine as per NICE guidelines (CG178 1.5.7.2). Methods Data collected retrospectively anonymously from all electronic notes via the UK-CRIS analysis platform. inclusion criteria required patients, aged 18–64 years, have a (ICD10 F20) diagnosis been admitted one ten Trust inpatient wards between 01/01/2020 01/01/2021. Patients fulfil resistance, having inadequate response more antipsychotic drugs, which atypical agent. who had previously tried currently on excluded. Those non-schizophrenia psychotic disorders also 347,645 records electronically screened according criteria, 209 reviewed. Results 43 patients reviewed found be eligible for clozapine. 28 (65%) during their admission 9 these started titration process (21% those eligible). Of 19 declined when offered, 14 refused drug most common reason accepting blood monitoring (n=10). 15 clozapine, clinical team documented consideration offer in 6 (14%) but rejected its, predominantly due concerns non-compliance. For 3 (7%) considered did There no documentation regarding (14%). Conclusion This identified that TRS admission. However, proportion gold standard this may lead poorer outcomes. It demonstrated minority ultimately start drug. are barriers accept instance around regular required.